Eleonore Fröhlich1, Peter Brossart, Richard Wahl. 1. Department of Endocrinology, Metabolism, Nephrology and Clinical Chemistry, Internal Medicine, University of Tuebingen, Tuebingen, Germany.
Abstract
PURPOSE: Retinoic acid presently is the most advanced agent able to improve the efficacy of radioiodine therapy in differentiated thyroid carcinoma. In order to identify compounds with higher efficacy a panel of pharmacologically well-characterized compounds with antitumour action in solid cancer cell lines was screened. METHODS: The effects of the compounds on iodide uptake, cell number, proliferation and apoptosis were evaluated. RESULTS: In general, compounds were more effective in cell lines derived from more aggressive tumours. The effectiveness in terms of number of responsive cell lines and maximal increase in iodide uptake achieved decreased in the order: APHA > valproic acid approximately sirolimus approximately arsenic trioxide > retinoic acid approximately lovastatin > apicidine approximately azacytidine approximately retinol approximately rosiglitazone approximately bortezomib. CONCLUSION: We hypothesize that testing of cells from primary tumours or metastases in patients may be a way to identify compounds with optimum therapeutic efficacy for individualized treatment.
PURPOSE:Retinoic acid presently is the most advanced agent able to improve the efficacy of radioiodine therapy in differentiated thyroid carcinoma. In order to identify compounds with higher efficacy a panel of pharmacologically well-characterized compounds with antitumour action in solid cancer cell lines was screened. METHODS: The effects of the compounds on iodide uptake, cell number, proliferation and apoptosis were evaluated. RESULTS: In general, compounds were more effective in cell lines derived from more aggressive tumours. The effectiveness in terms of number of responsive cell lines and maximal increase in iodide uptake achieved decreased in the order: APHA > valproic acid approximately sirolimus approximately arsenic trioxide > retinoic acid approximately lovastatin > apicidine approximately azacytidine approximately retinol approximately rosiglitazone approximately bortezomib. CONCLUSION: We hypothesize that testing of cells from primary tumours or metastases in patients may be a way to identify compounds with optimum therapeutic efficacy for individualized treatment.
Authors: Electron Kebebew; Miao Peng; Emily Reiff; Patrick Treseler; Kenneth A Woeber; Orlo H Clark; Francis S Greenspan; Sheila Lindsay; Quan-Yang Duh; Eugene Morita Journal: Surgery Date: 2006-12 Impact factor: 3.982
Authors: H Tedesco Silva; C R Felipe; P G P Machado; R Garcia; S Motegi; B H Hosaka; N M Hanzawa; S I Park; D Casarini; V C Lima; M Franco; J O Medina-Pestana Journal: Transplant Proc Date: 2003-05 Impact factor: 1.066
Authors: M F Herrera; I D Hay; P S Wu; J R Goellner; J J Ryan; J R Ebersold; E J Bergstralh; C S Grant Journal: World J Surg Date: 1992 Jul-Aug Impact factor: 3.352
Authors: Geneviève Dom; Vanessa Chico Galdo; Maxime Tarabichi; Gil Tomás; Aline Hébrant; Guy Andry; Viviane De Martelar; Frédérick Libert; Emmanuelle Leteurtre; Jacques E Dumont; Carine Maenhaut; Wilma C G van Staveren Journal: Thyroid Date: 2013-03 Impact factor: 6.568
Authors: V Maggisano; C Puppin; M Celano; M D'Agostino; M Sponziello; S Micali; M Navarra; G Damante; S Filetti; D Russo Journal: Endocrine Date: 2013-05-01 Impact factor: 3.633